Literature DB >> 29869609

Case Report: Mucosal Leishmaniasis Presenting with Nasal Septum Perforation after Almost Thirty Years.

Jesùs Rojas-Jaimes1,2, Helena L Frischtak3, Jose Arenas4, Andres G Lescano5.   

Abstract

Mucosal leishmaniasis (ML) is associated with progressive tissue destruction and granuloma formation, often after a considerable period of latency from an initial cutaneous infection. We report a case of recurrent epistaxis of 3 years duration and nasopharyngeal obstruction in a woman with treated cutaneous leishmaniasis nearly 30 years before and with no further exposure to Leishmania. Computed tomography revealed nasal septal perforation and histopathology demonstrated chronic inflammation. Microscopy was negative for amastigotes, but molecular testing of nasal mucosa biopsy detected Leishmania (Viannia) braziliensis. The patient underwent 28 days of treatment with IV sodium stibogluconate and her symptoms improved significantly. Sixteen months after treatment, she continues to have episodic epistaxis and detectable parasite load in her nasal lesion. Although ML is known to take years to decades to develop, there are few reported cases in the literature of such a long latency period. This report highlights the importance of considering ML in the differential diagnosis of chronic epistaxis in countries where leishmaniasis is endemic or in immigrants from these countries, even when presentation occurs decades after leaving an endemic region.

Entities:  

Mesh:

Substances:

Year:  2018        PMID: 29869609      PMCID: PMC6090329          DOI: 10.4269/ajtmh.17-0831

Source DB:  PubMed          Journal:  Am J Trop Med Hyg        ISSN: 0002-9637            Impact factor:   2.345


  26 in total

1.  Efficacy of sodium stibogluconate alone and in combination with allopurinol for treatment of mucocutaneous leishmaniasis.

Authors:  A Llanos-Cuentas; J Echevarría; M Cruz; A La Rosa; P Campos; M Campos; E Franke; J Berman; F Modabber; J Marr
Journal:  Clin Infect Dis       Date:  1997-09       Impact factor: 9.079

2.  Onset of espundia after many years of occult infection with Leishmania braziliensis.

Authors:  B C Walton; L V Chinel; O Eguia y Eguia
Journal:  Am J Trop Med Hyg       Date:  1973-11       Impact factor: 2.345

3.  Polymerase chain reaction detection of Leishmania kDNA from the urine of Peruvian patients with cutaneous and mucocutaneous leishmaniasis.

Authors:  Nicolas Veland; Diego Espinosa; Braulio Mark Valencia; Ana Pilar Ramos; Flor Calderon; Jorge Arevalo; Donald E Low; Alejandro Llanos-Cuentas; Andrea K Boggild
Journal:  Am J Trop Med Hyg       Date:  2011-04       Impact factor: 2.345

Review 4.  Epistaxis: an update on current management.

Authors:  L E R Pope; C G L Hobbs
Journal:  Postgrad Med J       Date:  2005-05       Impact factor: 2.401

5.  Effect of combination therapy with systemic glucantime and pentoxifylline in the treatment of cutaneous leishmaniasis.

Authors:  G Sadeghian; M A Nilforoushzadeh
Journal:  Int J Dermatol       Date:  2006-07       Impact factor: 2.736

Review 6.  Leishmaniasis.

Authors:  B L Herwaldt
Journal:  Lancet       Date:  1999-10-02       Impact factor: 79.321

Review 7.  Cutaneous leishmaniasis.

Authors:  Richard Reithinger; Jean-Claude Dujardin; Hechmi Louzir; Claude Pirmez; Bruce Alexander; Simon Brooker
Journal:  Lancet Infect Dis       Date:  2007-09       Impact factor: 25.071

8.  Imported mucosal leishmaniasis in a traveler.

Authors:  A Scope; H Trau; M Bakon; N Yarom; A Nasereddin; E Schwartz
Journal:  Clin Infect Dis       Date:  2003-08-28       Impact factor: 9.079

Review 9.  Complementary exams in the diagnosis of American tegumentary leishmaniasis.

Authors:  Ciro Martins Gomes; Natália Aparecida de Paula; Orlando Oliveira de Morais; Killarney Ataíde Soares; Ana Maria Roselino; Raimunda Nonata Ribeiro Sampaio
Journal:  An Bras Dermatol       Date:  2014 Sep-Oct       Impact factor: 1.896

10.  Efficacy and safety of single-dose liposomal amphotericin B for visceral leishmaniasis in a rural public hospital in Bangladesh: a feasibility study.

Authors:  Dinesh Mondal; Jorge Alvar; Md Golam Hasnain; Md Shakhawat Hossain; Debashis Ghosh; M Mamun Huda; Shah Golam Nabi; Shyam Sundar; Greg Matlashewski; Byron Arana
Journal:  Lancet Glob Health       Date:  2013-12-05       Impact factor: 26.763

View more
  2 in total

1.  Severe mucosal leishmaniasis with torpid and fatal evolution.

Authors:  Jesús Rojas Jaimes
Journal:  Clin Case Rep       Date:  2022-08-14

2.  Successful treatment by adding thalidomide to meglumine antimoniate in a case of refractory anthroponotic mucocutaneous leishmaniasis.

Authors:  Vahid Mashayekhi Goyonlo; Sadegh Vahabi-Amlashi; Faezeh Taghavi
Journal:  Int J Parasitol Drugs Drug Resist       Date:  2019-08-27       Impact factor: 4.077

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.